Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial - 23/11/23
, Amelia R Hofstetter, PhD b, Ana M Ortega-Villa, PhD c, Prossy Naluyima, PhD a, Francis Kiweewa, MD a, Immaculate Nakabuye, BPH a, Galina V Yamshchikov, MS b, Charla Andrews, MS b, Mark O'Callahan, BS b, Larisa Strom, MPH b, Steven Schech, BS d, e, Leigh Anne Eller, PhD d, e, Erica L Sondergaard, BSN d, e, Paul T Scott, MD d, Mihret F Amare, MBA d, e, Kayvon Modjarrad, MD d, Amir Wamala, MPH a, Allan Tindikahwa, BPharm a, Ezra Musingye, BStat a, Jauhara Nanyondo, MPH a, Martin R Gaudinski, MD b, Ingelise J Gordon, RN b, LaSonji A Holman, FNP b, Jamie G Saunders, BSN b, Pamela J M Costner, RN b, Floreliz H Mendoza, RN b, Myra Happe, PhD b, Patricia Morgan, MS b, Sarah H Plummer, MSN b, Somia P Hickman, PhD b, Sandra Vazquez, MS b, Tamar Murray, BS b, Jamilet Cordon, BS b, Caitlyn N M Dulan, MS b, Ruth Hunegnaw, PhD b, Manjula Basappa, BS b, Marcelino Padilla, BS b, Suprabhath R Gajjala, MS b, Phillip A Swanson, PhD b, Bob C Lin, BS b, Emily E Coates, PhD b, Jason G Gall, PhD b, Adrian B McDermott, PhD b, Richard A Koup, MD b, John R Mascola, MD b, Aurélie Ploquin, PhD b, Nancy J Sullivan, PhD b, Hannah Kibuuka, MD a, *, Julie A Ake, MD d, *, Julie E Ledgerwood, DO b, *RV 508 Study Team†
Summary |
Background |
Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among 164 confirmed cases in the second half of 2022. Although vaccines and therapeutics specific for Zaire Ebola virus have been approved for use during outbreak situations, Sudan Ebola virus is an antigenically distinct virus with no approved vaccines available.
Methods |
In this phase 1, open-label, dose-escalation trial we evaluated the safety, tolerability, and immunogenicity of a monovalent chimpanzee adenovirus 3 vaccine against Sudan Ebola virus (cAd3-EBO S) at Makerere University Walter Reed Project in Kampala, Uganda. Study participants were recruited from the Kampala metropolitan area using International Review Board-approved written and electronic media explaining the trial intervention. Healthy adults without previous receipt of Ebola, Marburg, or cAd3 vectored-vaccines were enrolled to receive cAd3-EBO S at either 1 × 1010 or 1 × 1011 particle units (PU) in a single intramuscular vaccination and were followed up for 48 weeks. Primary safety and tolerability endpoints were assessed in all vaccine recipients by reactogenicity for the first 7 days, adverse events for the first 28 days, and serious adverse events throughout the study. Secondary immunogenicity endpoints included evaluation of binding antibody and T-cell responses against the Sudan Ebola virus glycoprotein, and neutralising antibody responses against the cAd3 vector at 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, NCT04041570, and is completed.
Findings |
40 healthy adults were enrolled between July 22 and Oct 1, 2019, with 20 receiving 1 × 1010 PU and 20 receiving 1 × 1011 PU of cAd3-EBO S. 38 (95%) participants completed all follow-up visits. The cAd3-EBO S vaccine was well tolerated with no severe adverse events. The most common reactogenicity symptoms were pain or tenderness at the injection site (34 [85%] of 40), fatigue (29 [73%] of 40), and headache (26 [65%] of 40), and were mild to moderate in severity. Positive responses for glycoprotein-specific binding antibodies were induced by 2 weeks in 31 (78%) participants, increased to 34 (85%) participants by 4 weeks, and persisted to 48 weeks in 31 (82%) participants. Most participants developed glycoprotein-specific T-cell responses (20 [59%, 95% CI 41–75] of 34; six participants were removed from the T cell analysis after failing quality control parameters) by 4 weeks after vaccination, and neutralising titres against the cAd3 vector were also increased from baseline (90% inhibitory concentration of 47, 95% CI 30–73) to 4 weeks after vaccination (196, 125–308).
Interpretation |
The cAd3-EBO S vaccine was safe at both doses, rapidly inducing immune responses in most participants after a single injection. The rapid onset and durability of the vaccine-induced antibodies make this vaccine a strong candidate for emergency deployment in Sudan Ebola virus outbreaks.
Funding |
National Institutes of Health via interagency agreement with Walter Reed Army Institute of Research.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 12
P. 1408-1417 - décembre 2023 Retour au numéro
Article précédent
- Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews
- Stefan Litvinjenko, Olivia Magwood, Shishi Wu, Xiaolin Wei
- Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study
- Dimie Ogoina, Mahmood Muazu Dalhat, Ballah Akawu Denue, Mildred Okowa, Nneka Marian Chika-Igwenyi, Hakeem Abiola Yusuff, Umenzekwe Chukwudi Christian, Olukemi Adekanmbi, Anastacia Okwudili Ojimba, John Tunde Aremu, Kambai Lalus Habila, Sebastine Oseghae Oiwoh, Ekaete Alice Tobin, Simon Mafuka Johnson, Abimbola Olaitan, Chizaram Onyeaghala, Simji Samuel Gomerep, Datonye Alasia, Asukwo E Onukak, Juliet Mmerem, Uche Unigwe, Olanrewaju Falodun, Vivian Kwaghe, Sati Klein Awang, Mogaji Sunday, Chiedozie James Maduka, Aliyu Mamman Na'uzo, Sampson Omagbemi Owhin, Abdullahi Asara Mohammed, Mukhtar Abdulmajid Adeiza, Nigerian Infectious Diseases Society Mpox Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?